Approaching the final week of November CSL Ltd ADR (OTCMKTS: CSLLY) received some good news as the United States Food and Drug Administration approved CSL Behring’s new gene therapy drug, HEMEGENIX ...
Narrow-moat CSL reported fiscal 2024 revenue of USD 14.8 billion and net profit after tax before amortization of USD 2.9 billion, up 11% and 15% in constant currency, respectively, close to our ...
CSL Limited has left its current fiscal year financial guidance unchanged, which I deem to be too conservative. There are various indicators suggesting that the company's actual topline expansion and ...
MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global ...
(RTTNews) - CSL Behring Canada Inc., a unit of CSL Ltd. (CMXHF.PK), Monday announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public ...
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and ...
Australian biopharma CSL has a rich history. The company, which was originally called Commonwealth Serum Laboratories, was started by the government during World War I as a means to get critical ...
CSL Behring has been honored with this prestigious award recognizing innovation and excellence in pharmaceutical facility projects, as the FOYA program celebrates its 20 th anniversary "As FOYA marks ...
Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback